For people living with epilepsy, seizure clusters can occur suddenly and often require immediate intervention. While rescue medications have been available for years, awareness of treatment options has historically lagged behind medical innovation.
As newer, easy-to-administer rescue therapies entered the market, pharmaceutical companies began investing in advocacy partnerships, patient ambassador initiatives, caregiver education programs, and influencer-driven awareness campaigns. These efforts helped improve visibility while encouraging conversations about seizure preparedness and emergency treatment.
According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 3.4 million Americans live with active epilepsy, including around 470,000 children. The burden extends globally, with the World Health Organization (WHO) estimating that more than 50 million people worldwide live with epilepsy.
The Rise of Easy-to-Administer Seizure Rescue Therapies
Historically, seizure rescue treatments often required administration methods that some caregivers found challenging during emergencies.
The introduction of nasal spray rescue medications changed the treatment landscape. These products offered a non-invasive and easier-to-administer option, making them more practical in schools, workplaces, public settings, and at home.
The U.S. Food and Drug Administration (FDA) has approved two major nasal spray seizure cluster treatments in the United States: VALTOCO (diazepam nasal spray) and NAYZILAM (midazolam nasal spray).
These products have become highly visible not only because of their clinical utility but also because of their strong awareness and patient engagement initiatives.
VALTOCO: One of the Most Active Brands in Advocacy Marketing
VALTOCO, developed by Neurelis, is widely recognized as one of the strongest examples of advocacy-driven awareness within the seizure rescue medication market.
Following FDA approval in 2020, the company expanded its educational outreach through partnerships with epilepsy advocates, patients, caregivers, and community organizations.
Rather than focusing solely on product promotion, VALTOCO campaigns emphasized real-life experiences of individuals managing seizure clusters. Patients and caregivers shared stories about school participation, employment challenges, travel concerns, and emergency preparedness.
The company also collaborated with epilepsy advocate Rick Harrison to increase public awareness of seizure emergencies and treatment planning.
These ambassador-led initiatives helped the brand reach audiences beyond traditional healthcare channels and contributed significantly to its visibility within the epilepsy community.
NAYZILAM: Strengthening Visibility Through Education and Community Engagement
NAYZILAM, marketed by UCB, represents another leading seizure cluster medication that has benefited from advocacy-based awareness efforts.
After receiving FDA approval in 2019, NAYZILAM became an important treatment option for seizure clusters in patients with epilepsy.
While the brand has focused heavily on educational outreach and patient support resources, it has also participated in broader epilepsy awareness efforts involving advocacy organizations, caregiver communities, and educational campaigns.
These initiatives have encouraged discussions about seizure action plans, treatment accessibility, and emergency preparedness among patients and caregivers.
Advocacy Organizations Have Amplified Brand Awareness
The success of these medications has also been supported by strong advocacy networks.
Organizations such as the Epilepsy Foundation have played a major role in increasing public understanding of seizure disorders. Through ambassador programs, awareness campaigns, educational events, and patient storytelling initiatives, these organizations have helped connect patients with information about available treatment options.
Many epilepsy ambassadors share their experiences through conferences, webinars, public speaking engagements, and social media platforms. Their personal stories often create greater engagement than traditional advertising campaigns.
This has allowed seizure rescue medication brands to gain visibility through trusted community voices rather than relying entirely on direct promotional activities.
Drug Brands Successfully Using Advocacy, Influencer, or Ambassador Programs
| Drug Brand | Company | Administration Method | Advocacy / Ambassador Activities |
|---|---|---|---|
| VALTOCO (Diazepam Nasal Spray) | Neurelis | Nasal Spray | Patient ambassadors, caregiver advocacy, influencer collaborations, epilepsy awareness campaigns, community outreach programs |
| NAYZILAM (Midazolam Nasal Spray) | UCB | Nasal Spray | Educational campaigns, patient support initiatives, advocacy partnerships, caregiver engagement programs |
| DIASTAT AcuDial (Diazepam Rectal Gel) | Legacy Brand | Rectal Gel | Primarily healthcare education; limited public-facing ambassador activity compared with newer brands |
Government and Public Health Statistics
According to the CDC, approximately 3.4 million people in the United States currently live with active epilepsy.
CDC data also shows that about 470,000 U.S. children are affected by active epilepsy.
According to the WHO, epilepsy affects more than 50 million people globally, making it one of the world’s most common neurological disorders.
Research referenced by federal health agencies indicates that nearly 30% of epilepsy patients continue to experience seizures despite anti-seizure medication therapy, creating an ongoing need for effective rescue treatments.
Key Statistics at a Glance
| Metric | Value |
| Americans living with active epilepsy (CDC) | 3.4 Million |
| U.S. children with active epilepsy (CDC) | 470,000 |
| Global epilepsy population (WHO) | 50+ Million |
| Patients with drug-resistant epilepsy | Approximately 30% |
| FDA-approved nasal spray seizure rescue therapies | 2 Major Brands |
| Most commonly used modern rescue format | Nasal Spray |
The growing visibility of seizure rescue medications demonstrates how healthcare communication has evolved.
Brands such as VALTOCO and NAYZILAM have successfully combined medical education with patient advocacy, ambassador programs, caregiver engagement, and awareness initiatives. Supported by organizations such as the Epilepsy Foundation, these efforts have helped increase public understanding of seizure clusters while providing patients and families with valuable educational resources.
As awareness continues to expand, advocacy-driven outreach is likely to remain an important strategy for improving recognition of seizure emergencies and ensuring patients are informed about available treatment options.
Get Easy Access
From drug pipelines and clinical trials to approvals and company strategies, everything you need to track the drugs industry is available in one dashboard. From regional trends to innovation tracking, everything is organized in a single platform for faster, smarter decisions.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting delivers strategic intelligence and market expertise for the global drugs market. We work with pharmaceutical companies, manufacturers, and healthcare stakeholders to analyze industry trends, competitive landscapes, government data, and evolving treatment demands. Our insights help businesses strengthen product development, identify growth opportunities, and adapt to the rapidly changing pharmaceutical environment.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium